Opioid receptors in the GI tract: targets for treatment of both diarrhea and constipation in functional bowel disorders?
| Autor: | Maura Corsetti, J Pannemans |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Diarrhea
medicine.medical_specialty Eluxadoline Constipation Narcotic Antagonists Phenylalanine Receptors Opioid mu Gastroenterology Polyethylene Glycols 03 medical and health sciences Naloxegol chemistry.chemical_compound 0302 clinical medicine Naldemedine Internal medicine Drug Discovery medicine Animals Humans Antidiarrheals Defecation Irritable bowel syndrome Pharmacology business.industry Imidazoles Chronic pain Inflammatory Bowel Diseases medicine.disease Methylnaltrexone Naltrexone Analgesics Opioid Gastrointestinal Tract Quaternary Ammonium Compounds Morphinans Opioid chemistry Laxatives 030211 gastroenterology & hepatology medicine.symptom Gastrointestinal Motility business 030217 neurology & neurosurgery Signal Transduction medicine.drug |
| Zdroj: | Current Opinion in Pharmacology. 43:53-58 |
| ISSN: | 1471-4892 |
| DOI: | 10.1016/j.coph.2018.08.008 |
| Popis: | Opioids have been used for centuries, mostly as a sedative and to treat pain. Currently, they are used on a global scale for the treatment of acute and chronic pain in diseases as osteoarthritis, fibromyalgia, and low back pain. Binding of opioids on opioid receptors can cause a range of different effects such as changes in stress response, analgesia, motor activity and autonomic functions. This review provide a synthetic summary of the most recent literature on the use of drugs acting on mu-receptors to treat two prevalent functional bowel disorders, presenting with opposite bowel habit. Eluxadoline and naloxegol, methylnaltrexone and naldemedine are recently FDA and/or EMA approved drugs demonstrated to be effective and safe for treatment respectively of irritable bowel syndrome subtype diarrhea and opioid induced constipation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect